Literature DB >> 9890943

Fc receptor-mediated platelet activation is dependent on phosphatidylinositol 3-kinase activation and involves p120(Cbl).

A Saci1, S Pain, F Rendu, C Bachelot-Loza.   

Abstract

The platelet receptor for the Fc domain of IgGs (FcgammaRIIa) triggers intracellular signaling through protein tyrosine phosphorylations leading to platelet aggregation. In this study, we focused on the adaptor protein p120(cbl) (Cbl), which became tyrosine-phosphorylated after platelet activation induced by antibodies. Cbl phosphorylation was dependent on Fc receptor engagement. An association of Cbl with the p85 subunit of phosphatidylinositol 3-kinase (PI 3-K) occurred in parallel with Cbl tyrosine phosphorylation. We showed by in vitro experiments that Cbl/p85 association was mediated by the Src homology 3 domain of p85/PI 3-K and the proline-rich region of Cbl. Inhibition of PI 3-K activity by wortmannin led to the blockade of both platelet aggregation and serotonin release mediated by FcgammaRIIa engagement, whereas it only partly inhibited those induced by thrombin. Thus, PI 3-K may play a crucial role in the initiation of platelet responses after FcgammaRIIa engagement. Our results suggest that Cbl is involved in platelet signal transduction by the recruitment of PI 3-K to the FcgammaRIIa pathway, possibly by increasing PI 3-K activity.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9890943     DOI: 10.1074/jbc.274.4.1898

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  7 in total

1.  Platelet alpha IIb-beta 3 integrin engagement induces the tyrosine phosphorylation of Cbl and its association with phosphoinositide 3-kinase and Syk.

Authors:  A Saci; F Rendu; C Bachelot-Loza
Journal:  Biochem J       Date:  2000-11-01       Impact factor: 3.857

2.  Contrasting requirements for ubiquitylation during Fc receptor-mediated endocytosis and phagocytosis.

Authors:  James W Booth; Moo-Kyung Kim; Andrzej Jankowski; Alan D Schreiber; Sergio Grinstein
Journal:  EMBO J       Date:  2002-02-01       Impact factor: 11.598

3.  Analysis of FcgammaRIIA cytoplasmic tail requirements in signaling for serotonin secretion: evidence for an ITAM-dependent, PI3K-dependent pathway.

Authors:  A B Daniels; R G Worth; R J Dickstein; J S Dickstein; T-H Kim-Han; M-K Kim; A D Schreiber
Journal:  Scand J Immunol       Date:  2010-04       Impact factor: 3.487

4.  Differential effect of the inhibition of Grb2-SH3 interactions in platelet activation induced by thrombin and by Fc receptor engagement.

Authors:  Abdelhafid Saci; Wang-Qing Liu; Michel Vidal; Christiane Garbay; Francine Rendu; Christilla Bachelot-Loza
Journal:  Biochem J       Date:  2002-05-01       Impact factor: 3.857

5.  Genetic polymorphisms of FCGR2A encoding Fcγ receptor IIa in a Japanese population and functional analysis of the L273P variant.

Authors:  Minoru Tada; Akiko Ishii-Watabe; Keiko Maekawa; Hiromi Fukushima-Uesaka; Kouichi Kurose; Takuo Suzuki; Nahoko Kaniwa; Jun-Ichi Sawada; Nana Kawasaki; Takako Eguchi Nakajima; Ken Kato; Yasuhide Yamada; Yasuhiro Shimada; Teruhiko Yoshida; Takashi Ura; Miyuki Saito; Kei Muro; Toshihiko Doi; Nozomu Fuse; Takayuki Yoshino; Atsushi Ohtsu; Nagahiro Saijo; Haruhiro Okuda; Tetsuya Hamaguchi; Yoshiro Saito; Yasuhiro Matsumura
Journal:  Immunogenetics       Date:  2012-08-18       Impact factor: 2.846

6.  Eptifibatide-induced thrombocytopenia and thrombosis in humans require FcgammaRIIa and the integrin beta3 cytoplasmic domain.

Authors:  Cunji Gao; Brian Boylan; Dan Bougie; Joan C Gill; Jessica Birenbaum; Debra K Newman; Richard H Aster; Peter J Newman
Journal:  J Clin Invest       Date:  2009-02-09       Impact factor: 14.808

7.  Dengue virus nonstructural protein 1 activates platelets via Toll-like receptor 4, leading to thrombocytopenia and hemorrhage.

Authors:  Chiao-Hsuan Chao; Wei-Chueh Wu; Yen-Chung Lai; Pei-Jane Tsai; Guey-Chuen Perng; Yee-Shin Lin; Trai-Ming Yeh
Journal:  PLoS Pathog       Date:  2019-04-22       Impact factor: 6.823

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.